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Two herpes simplex virus mutants containing mutated residues within the conserved Exo III motif of the polymerase gene
were previously shown to be defective in 39–59 exonuclease activity and exhibited extremely high mutation frequencies. In
this study, we have shown that these mutants also exhibited higher resistance to phosphonoacetic acid and sensitivity to
aphidicolin and all nucleoside analogs tested, including acyclovir and gancicolvir, compared to wild-type virus. Marker
transfer experiments and sequencing analyses demonstrated that these altered phenotypes were the result of mutations
within the Exo III motif. The data indicate that, aside from leading to exonuclease deficiency, mutations in the Exo III motif
may also affect interaction of nucleoside triphosphates with the catalytic sites of polymerase activity. © 1998 Academic Press
INTRODUCTION
The catalytic subunit of herpes simplex virus (HSV)2
DNA polymerase (pol) possesses polymerase and 39–59
exonuclease activity (Knopf, 1979; Knopf and Weisshart,
1990; Marcy et al., 1990). Protein sequence alignment of
HSV Pol and other DNA polymerases reveals several
homologous regions, designated regions I through VII
(Gibbs et al., 1988; Hwang et al., 1992). HSV Pol also
contains a conserved d region C shared among other
eukaryotic viral DNA polymerases (Coen, 1996; Hwang et
al., 1997), and DNA polymerase d (Zhang et al., 1991) and
e (Kesti et al., 1993). Importantly, most HSV mutants
conferring resistance to certain antiviral drugs have mu-
tations within the conserved regions, including regions I,
II, III, V, and VII and d region C (Gibbs et al., 1988; Hwang
et al., 1992; Larder et al., 1987; Wang et al., 1992). Since
these antiviral drugs mimic and/or compete with the
natural substrates for incorporation by the viral DNA Pol,
resistance to these antiviral drugs can result from altered
specificity during insertion of these analogs. Further-
more, HSV pol mutants exhibiting resistance to nucleo-
side analogs are usually accompanied by altered sensi-
tivities to phosphonoacetic acid (PAA), which is thought
to be a pyrophosphate analog, and aphidicolin. There-
fore, it had been suggested that these conserved regions
are directly or indirectly involved in recognition and bind-
ing of substrates and pyrophosphate (reviewed in Coen,
1996).
The 39–59 exonuclease activity of HSV Pol is located in
the N-terminal half of the protein, which contains three
highly conserved motifs (Exo I, II, and III) (Fig. 1A) based
on protein sequence alignments among several Pols
containing exonuclease activity. Examination of mutant
Pols containing mutations within these Exo motifs of
Escherichia coli Pol I (Derbyshire et al., 1988, 1991; Free-
mont et al., 1988), Pols of bacteriophages (Frey et al.,
1993; Reha-Krantz and Nonay, 1993; Reha-Krantz et al.,
1991; Soengaas et al., 1992), and yeast Pol d (Morrison et
al., 1991; Simon et al., 1991) confirmed that these con-
served motifs are critical for 39–59 exonuclease activity,
and some mutants, if not lethal, have mutator phenotypes
(Frey et al., 1993). Similarly, HSV Pol mutants containing
mutations within these motifs are severely impaired in
exonuclease activity (Hall et al., 1995; Hwang et al., 1997;
Ku¨hn and Knopf, 1996). For example, two Exo III mutants,
Y7 and YD12, have been shown previously to be able to
replicate in Vero cells, yet they exhibit 300- to 800-fold
increases in the mutation frequencies of the thymidine
kinase (tk) gene, compared to wild-type strain KOS
(Hwang et al., 1997). Their extremely high mutation fre-
quencies are presumably due to impaired exonuclease
activities; only less than 2%, if any, of wild-type activity is
displayed by these two mutants. This finding suggests
that the proofreading function of 39–59 exonuclease ac-
tivity intrinsic to HSV Pol may not be absolutely essential
for the function of HSV pol and DNA replication.
Previous reports (Gibbs et al., 1988; Hall et al., 1989;
Wang et al., 1992) have demonstrated that certain HSV-1
mutants with altered drug sensitivities contain mutations
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in the N-terminal half of the pol gene, including se-
quences nearby and upstream of the Exo III motif. How-
ever, their exonuclease capabilities have not been char-
acterized. In this study, we have characterized the phe-
notypes of two Exo III mutants, Y7 and YD12. In addition
to the loss of exonuclease activity, both mutants exhibit
altered drug sensitivities. These results suggest that the
conserved Exo III motif of HSV Pol may play an important
role in maintaining the proper structure of the catalytic
site of polymerase activity, in addition to its role in exo-
nuclease activity.
RESULTS
Recombinant Pols containing the Exo III mutations
are resistant to PAA
Earlier studies (Gibbs et al., 1988; Hall et al., 1989;
Hwang et al., 1997; Larder et al., 1987; Wang et al., 1992)
demonstrate that HSV pol mutants with mutations lo-
cated upstream and downstream of the Exo III motif can
confer altered drug sensitivities. Because the Exo III
motif lies at the center of the conserved d region C, we
therefore hypothesized that mutations of the Exo III motif
might also exhibit altered drug sensitivities. To test this
hypothesis, we began to examine the effects of PAA on
the polymerase activities of the wild-type, Y7, and YD12
recombinant HSV-1 Pols which were expressed and pu-
rified from recombinant baculovirus-infected insect Sf9
cells (Hwang et al., 1997). By the standard gap-filling
reactions, the polymerase activity of wild-type Pol was
significantly inhibited by PAA, with an effective dose
inhibiting 50% of activity (ED50) at 6 mg/ml, while the
Klenow fragment of E. coli Pol I, which was known to be
resistant to PAA, had an ED50 at 6 mg/ml, while the
Klenow fragment of E. coli Pol I, which was known to be
resistant to PAA, had an ED50 of .100 mg/ml. As ex-
pected, mutant Pol Y7 and YD12 were resistant to the
inhibitory effects of PAA, with an ED50 of .100 and 28
mg/ml, respectively (Fig. 2). Therefore, both Y7 and YD12
mutant Pols were highly resistant to PAA.
The Exo III mutants of HSV-1 pol exhibit altered drug
sensitivities
With recombinant viruses available, we also exam-
ined their sensitivities to various antiviral drugs, in-
FIG. 1. (A) HSV Pol open reading frame with regions of sequence similarity. Conserved amino acid regions I to VII, and d region C, which overlap
the Exo III motif, among diverse DNA polymerases are shown as empty boxes. The dark boxes indicate the conserved Exo I, II, and III motifs critical
for 39–59 exonuclease activity. The numbers above the line refer to amino acid residues of HSV Pol. Sequences shown below the line are the Exo
III residues of HSV Pol; the altered amino acids in mutant Y7 and YD12 are also indicated. (B). Maps of SmaI and KpnI restriction sites of the HSV
pol gene. The box below the map shows the DNA fragment which is able to rescue the altered drug sensitive phenotype of the Y7 mutant.
FIG. 2. Effects of PAA on polymerase activities of purified wild-type
(X), Y7 (), and YD12 (E) HSV Pols and the E. coli Pol I Klenow fragment
(h). Polymerase activity assays were performed as described under
Materials and Methods.
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cluding PAA, aphidicolin, ACV, GCV, AraA, AraT, ICdR,
and BVdU. Like most HSV pol mutants containing mu-
tations within conserved regions (Gibbs et al., 1988;
Hwang et al., 1992), both mutants were hypersensitive
to aphidicolin (Fig. 3) and resistant to PAA (Fig. 3B),
compared to wild-type virus. In contrast to most drug-
resistant mutants (Gibbs et al., 1988; Hwang et al.,
1992; Wang et al., 1992), which confer resistance to
both PAA and nucleoside analogs and map within the
polymerase domain, both mutants exhibited different
degrees of hypersensitivity to ACV (Fig. 3C), GCV (Fig.
3D), AraA (Fig. 3E), AraT (Fig. 3F), ICdR (Fig. 3G), and
BVdU (Fig. 3H). The ED50 results of each drug exhib-
ited by the wild-type, Y7, and YD12 viruses are sum-
marized in Table 1. Thus, both Exo III mutant viruses
are not only severely impaired in exonuclease activity
(Hwang et al., 1997), but also exhibit altered drug
sensitivities.
Y577H is the only change at the amino acid level in
the pol open reading frame of the Y7 mutant
Although both Exo III mutants were constructed to
contain the desired mutations, these mutants might
introduce an additional mutation(s) within the pol gene
due to their high mutation rates (Hwang et al., 1997),
and such unexpected change(s) might be attributed to
the altered drug sensitivities. To rule out this possibil-
ity, the entire open reading of the pol gene of the Y7
mutant was sequenced as described under Materials
and Methods. As expected, sequencing results re-
vealed a T to C change in codon 577 (change of TAC
to CAC), which changes tyrosine to histidine. In addi-
tion, a G to A change corresponding to nucleotide 459
of the pol gene was also found. However, this G to A
alteration does not alter the leucine codon at residue
153. Therefore, the pol gene of the Y7 mutant contains
FIG. 3. Effects of aphidicolin (A), PAA (B), ACV (C), GCV (D), AraA (E), AraT (F), ICdR (G), and BVdU (H) on plaque formation by wild-type KOS (X)
and the mutants Y7 () and YD12 (E) and the Kpn I 1.1-kb rescued Y7 virus (h). Plaque reduction assays were performed as described under Materials
and Methods.
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only the expected tyrosine to histidine mutation at the
amino acid level.
A DNA fragment containing the Exo III motif can
rescue the altered drug sensitivities
Sequencing data indicated that the Y577H mutation
was responsible for the altered drug sensitivities of mu-
tant Y7. To verify this further, we attempted to map the
region of the Y7 pol gene conferring the altered pheno-
type. Although mapping can be accomplished by trans-
ferring the PAA resistant (PAAr) marker of Y7 into wild-
type KOS virus, the progeny of transfection receiving the
PAAr marker of Y7 may generate an additional muta-
tion(s) if the marker is indeed the altered Exo III se-
quence. To avoid this potential problem, which may com-
plicate the interpretation of the data, we choose to res-
FIG. 3—Continued
TABLE 1
ED50 of Various Drugs on Wild-Type, Y7, and YD12 Viruses
PAA
(mg/ml)
Aphidicolin
(mg/ml)
ACV
(mM)
GCV
(mM)
AraA
(mM)
AraT
(mg/ml)
ICdR
(mg/ml)
BVdU
(mg/ml)
KOS 7 0.36 1.05 0.58 160 6 11 0.14
Y7 25 0.16 0.48 0.28 40 1.2 1.4 0.01
YD12 42 0.25 0.75 0.3 36 1.1 1.4 0.02
Note. The ED50, the concentration of each drug to reduce plaque formation by 50%, was determined directly from the plaque reduction curves
shown in Fig. 3.
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cue the hypersensitivity phenotype of Y7 to aphidicolin
(Aphhs) by using different DNA fragments derived from
the wild-type pol gene. The reason for using Y7 for
conducting these experiments is that the altered sensi-
tivity of Y7 to aphidicolin was sufficient to permit marker
rescue mapping of the Aphhs mutation. Experiments
were performed by cotransfection of the Y7 infectious
DNA with different DNA fragments derived from the wild-
type pol gene. The progeny of transfections using infec-
tious Y7 DNA alone formed no plaques in the presence
of 0.5 mg/ml of aphidicolin. In two different experiments
(Table 2), the 1.1-kb KpnI fragment of the wild-type pol
gene that includes the Exo III motif was able to rescue
the growth of Y7 effectively in the presence of 0.5 mg/ml
of aphidicolin. The 1.0- and 1.8-kb KpnI fragments and the
SmaI D fragment, which do not include the Exo III motif,
were not able to rescue the Aphhs marker. Therefore, the
marker conferring increased sensitivity to aphidicolin in
Y7 mapped to the 1022 bp within the 1.1-kb KpnI fragment
which includes the Exo III sequences, but excludes the
sequences within the SmaI D fragment (Fig. 1B).
Recombinant viruses resulting from the marker res-
cue experiments were plaque purified and their sen-
sitivities to various drugs were analyzed. These vi-
ruses exhibited sensitivities to aphidicolin, PAA, and
AraA indistinguishable from those of the wild-type KOS
virus (Figs. 3A, 3B, and 3E). However, they were highly
resistant to ACV, GCV, AraT, ICDR, and BVdU (Figs. 3C,
3D, 3F, 3G, and 3H). Since the HSV tk gene is required
for phosphorylation of these nucleoside analogs (Elion
et al., 1977; Cheng et al., 1983; Gentry and Aswell,
1975; Summers and Summers 1977; De Clerq et al.,
1979), with the exception of AraA (North and Cohen,
1979), their resistances to these drugs suggested that
they might contain tk mutations. It was possible that
these rescued recombinants were derived from preex-
isting tk mutations in infectious Y7 viral DNA used for
marker rescue experiments. Sequences flanking the
Exo III motif of these marker rescued recombinant
viruses were also analyzed as described above. These
recombinant viruses no longer contained the mutation
at residue 577. We conclude that, similar to other
mutations upstream and downstream of Exo III in d
region C (Gibbs et al., 1988; Larder et al., 1987; Wang
et al., 1992), the Y7 mutation altering the Exo III se-
quence can confer altered drug sensitivities in vitro
and in infected cells.
Alterations of the Exo III secondary structure induced
by mutations within the conserved d region C
The secondary structures of pol mutants containing
mutations within the d region C were analyzed by the
method of Garnier et al. (1978) via the PEPTIDESTRUC-
TURE and PLOTSTRUCTURE programs in GCG (Genetics
Computer Group; Wisconsin Package; Madison, Wiscon-
sin). While Exo III residues of wild-type Pol formed a
continuous b sheet structure (residues 570 to 587) (Fig.
4), this method predicted that this b sheet structure was
altered to form a turn structure in both Y7 and YD12
mutants. Interestingly, mutants Su1 (Wang et al., 1992),
RSC-26 (Larder et al., 1987), tsD9 (Gibbs et al., 1988), and
PFAr2 (Gibbs et al., 1988), which each confer altered drug
sensitivities, also altered the structure of residues in the
d region C (Fig. 4). It is possible that alterations of the
local structure within Exo III and the d region C might
also affect the proper structure of the catalytic sites of
polymerase activity, which would result in altered sensi-
tivities of these mutant pols to these drugs.
It is also notable that the structural alteration of the d
region C alone may not affect exonuclease activity, since
PFAr2 mutant Pol had been shown to display exonucle-
ase activity indistinguishable from that of the wild-type
Pol (Derse et al., 1982). Exonuclease activity requires the
Exo III motif, especially the conserved tyrosine and as-
partic acid residues, which have the catalytic activity per
se and bind the second divalent metal ion, respectively.
Therefore, the Exo III motif may have a role in maintain-
ing the proper structure of the catalytic sites of polymer-
ase activity, in addition to its role in the 39–59 exonucle-
ase activity.
TABLE 2
Marker Rescue of Aphhs Marker in Y7 Mutant Virus
Experiment No.
Progeny of Y7 DNA plus the following fragment:
None KpnI 1.0
KpnI
1.1 KpnI 1.8 SmaI C SmaI D
I ,0.04* ,0.4 3.6 ,0.09 ND ND
II ,0.03 ND 2.8 ND ND ,0.5
Note. Marker transfer experiments were performed by cotransfection of Y7 DNA prepared from mutant virus together with different DNA fragments
(Fig. 1B) derived from plasmid containing wild-type pol sequences. Progeny of transfectants were titered on Vero cells in the absence or the presence
of 0.5 mg/ml of aphidicolin. The efficiency of each DNA fragment to rescue the Aphhs of Y7 was expressed as the percentage of progeny (*) to form
plaques on Vero cells in the presence of 0.5 mg/ml of aphidicolin. Values underlined are considered positive for marker rescue. ND, not determined.
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DISCUSSION
The structural and functional independence of the
polymerase and exonuclease domains of HSV Pol has
been proposed (Haffey et al., 1990) according to the
model of E. coli Pol I (reviewed in Joyce and Steitz, 1994).
However, a previous study (Weisshart et al., 1994) indi-
cates that the catalytic sites for both polymerase and
exonuclease activities may reside on a single domain.
Alternatively, the catalytic site for polymerase activity
may reside on an independent structural domain but
requires functional interactions with other domains
(Weisshart et al., 1994). This result is based on the
biochemical analysis of different fragments of Pol after
limited proteolytic digestion. Other studies which dem-
onstrate that several mutant pols containing mutations
within or upstream of the conserved 39–59 exonuclease
activity site exhibit altered polymerase activity (Gibbs et
al., 1991; Hall et al., 1989; Wang et al., 1992) also impli-
cate the interdependence between exonuclease and
polymerase activities of HSV pol. It was possible that
these mutants with altered polymerase phenotypes
might be also associated with altered exonuclease ac-
tivity. However, the effects of these mutations on 39–59
exonuclease activity had not been demonstrated. In this
study, we demonstrate that two 39–59 exonuclease-defi-
cient pols can lead to the altered polymerase activity
with regard to the interactions with both pyrophosphate
and nucleoside analogs. These altered phenotypes are
due to mutations within the Exo III motif based on se-
quencing data and marker transfer experiments. Our
results further support the model of interdependence
between the exonuclease and polymerase activities of
HSV pol.
The altered drug sensitivities of both Y7 and YD12
mutants may also suggest that interactions with the
sugar, base, and phosphate moieties of dNTPs are al-
tered. Their high resistance to PAA reflected that these
mutations might have substantial alterations in the struc-
ture of the pyrophosphate exchange-release site which
could affect the interaction of catalytic site of polymerase
activity with the triphosphate moiety of nucleoside
triphosphates. Furthermore, the increased sensitivities of
both mutant Pols to all nucleoside analogs tested in this
study were substrate dependent. For example, both mu-
tants exhibited two- to fivefold increased sensitivity to
nucleoside analogs with altered sugar moieties, i.e.,
ACV, GCV, AraA, and AraT. Both ACV and GCV are
guanosine analogs lacking the 29 and 39 or the 29 moi-
eties, respectively. AraA and AraT are adenosine and
thymidine analogs, respectively, with the arabinosyl con-
formation at the 29 position. These results suggested that
both mutations could have intermediate effects on inter-
actions with the sugar moiety of nucleoside triphos-
phates. The substantially increased sensitivities of both
mutants to both ICdR and BVdU, which are nucleoside
analogs with altered structures of pyrimidine bases, also
suggested that these mutations could have dramatic
effects on their interactions with the base moiety of
nucleoside triphosphates. Thus, the mutated pol with
altered residues 577 and 581 could alter interactions
with the sugar, base, and triphosphate moieties of nu-
cleoside triphosphates, in addition to its loss of exonu-
clease activity (Hwang et al., 1997).
Although mutations in the Exo III motif and d region C
could alter drug sensitivity, it is currently unclear whether
residues within the Exo III motif and d region C could
have direct or indirect interactions with nucleoside
triphosphates. It is possible that they may function to
FIG. 4. Predicted alterations of the secondary structures of the Exo III and d region C. Secondary structure predictions were analyzed by the
method described in the text. The amino acid residues of the d region C of wild-type HSV-1 Pol are shown at the top; the numbers above it
refer to the amino acid residues. The predicted secondary structure (a, a-helical; b, b sheet; c, coil; and t, turn) of wild-type sequences is shown
below the sequences. The mutated residues are underlined. Only those with altered structure resulting from each mutation are shown. The
following mutations were analyzed: Y577H (mutant Y7), Y577H/D581A (mutant YD12); D531N (mutant Su1); E597D (mutant RSC-26); E597K
(mutant tsD9), and A605V (mutant PFAr2).
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maintain a proper structure in the catalytic sites of poly-
merase activity. Therefore, the effects of these mutated
residues on the structure of Pol demand further studies,
such as X-ray crystallographic analysis. Alternatively, it
will be of value if suppressor mutants can be isolated
from exonuclease-deficient pol to demonstrate that the
exonuclease-deficient phenotype can be reversed by
mutations within the catalytic sites of polymerase activity.
Such information would further support the model of
structural and functional interdependence between
these two activities of HSV pol.
MATERIALS AND METHODS
Cells and viruses
Vero cells were grown and maintained as described
(Hwang et al., 1997). HSV wild-type virus strain KOS and
its derivative Y7, which contains a single mutation (a
change of amino acid 577 from tyrosine to histidine;
Y577H), and YD12, which contains double changes (the
same change in Y577H plus a change of aspartic acid at
residue 581 to alanine; Y577H/D581A), were propagated
as described (Hwang et al., 1997).
Chemicals
All chemicals and antiviral drugs, except ganciclovir
(GCV; Syntex, Palo Alto, CA), used in this study were
purchased from Sigma (St. Louis, MO). Antiviral drug PAA
is a pyrophosphate analog and binds at the pyrophos-
phate exchange-release site of the Pol. Acyclovir (ACV)
and GCV are guanosine analogs lacking the 29 and 39 or
the 29 of sugar moieties, respectively. Arabinosyladenine
(AraA) and arabinosylthymidine (AraT) are adenine and
thymidine analogs, respectively, with arabinosyl confor-
mation at the 29 position. Iododeoxycytidine (ICdR) is a
cytidine analog containing iodine at the 59 position. Bro-
movinyldeoxyuridine (BVdU) is a thymidine analog with a
replacement of the 5-methyl group of the thymine base
with a bromovinyl group.
Polymerase activity assays
The standard gap-filling reactions (Marcy et al., 1990;
Hwang et al., 1997) were performed to determine the
sensitivity of wild-type and mutant Pol proteins to PAA.
Sensitivity of each Pol to PAA was determined by the
amount of [a-32P]dCTP incorporated into activated calf
thymus DNA under different concentrations of PAA and
measured in a liquid scintillation counter. The Klenow
fragment of E. coli Pol I was included as a control.
Drug assays
Plaque reduction assays were applied to determine
relative sensitivity to antiviral drugs as described previ-
ously (Hwang et al., 1992).
Sequencing of the pol genes
To confirm that Y7 virus contained only the Exo III
mutation, three DNA fragments were amplified from total
DNA prepared from Y7 infected Vero cells by polymerase
chain reaction (PCR) using three pairs of primers from
the pol gene, corresponding to nucleotides 218 to 21
(Pol-59) and 1593 to 1578 (2158L), 1189 to 1209 (1200R)
and 2180 to 2790 (3389L), and 2745 to 2765 (3325R) and
3734 to 3717 (Pol-39), where the A nucleotide of the first
ATG codon of the pol gene is defined as nucleotide 1. The
PCR products, which covered the entire open reading
frame of the pol gene, were then sequenced directly
using primers corresponding to the pol gene nucleotides
133 to 149 (712R), 210 to 190 (270L), 339 to 354 (920R), 431
to 350 (430R), 2921 to 2938 (2921R), 3073 to 3094 (3073R),
and 3432 to 3454 (4018R) and those described previously
(Hwang et al., 1997).
Marker rescue experiments and mutation mapping
Marker rescue was performed as described previ-
ously (Hwang et al., 1992) by using Y7 infectious DNA
and the KpnI or SmaI fragments of the wild-type pol gene
isolated from plasmid pSVK-pol (Hwang et al., 1997). To
confirm that the marker-rescued recombinant viruses
contained the wild-type sequence, the corresponding
1.1-kb KpnI fragment was amplified by PCR from crude
virion DNAs. The resulting DNAs were sequenced using
the corresponding primers.
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